← Search & browse all drugs
GENITO URINARY SYSTEM AND SEX HORMONES › SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM › ESTROGENS › Natural and semisynthetic estrogens, plain
chlorotrianisene
G03CA06
Forms & Strengths
- Capsules: 12 mg
- Capsules: 25 mg
Adult Dosing
- Menopausal symptoms: 12 to 25 mg daily orally for 30 days
- Atrophic vaginitis: 12 to 25 mg daily orally for 30 days
- Prostate carcinoma: 12 to 25 mg daily orally
Pediatric Dosing
- Not indicated in pediatric populations
Indications
- Palliative treatment of advanced prostate carcinoma
- Management of moderate to severe vasomotor symptoms associated with menopause
- Atrophic vaginitis
- Female hypogonadism
Mechanism of Action
- Synthetic, non-steroidal estrogen that binds to estrogen receptors in responsive tissues
- Stored in body fat and slowly released, providing a prolonged estrogenic effect
- Suppresses pituitary gonadotropin release
Contraindications
- Known or suspected pregnancy
- History of breast cancer or estrogen-dependent neoplasms
- Active thrombophlebitis, thromboembolic disorders, or stroke
- Undiagnosed abnormal genital bleeding
- Liver dysfunction or disease
Adverse Reactions
- Thromboembolism and thrombophlebitis
- Nausea, vomiting, abdominal cramps, bloating
- Breast tenderness and enlargement
- Edema and weight gain
- Headache, dizziness, migraine
- Cholestatic jaundice and hepatic dysfunction
Drug Interactions
- Anticoagulants (coumarin derivatives): decreased effectiveness due to increased clotting factor synthesis
- Rifampin and CYP3A4 inducers: may decrease estrogen plasma concentrations
- Corticosteroids: enhanced pharmacologic effects of corticosteroids
- Hepatotoxic drugs: increased risk of hepatotoxicity
Curated Content: Needs Vetting Before Put to Clinical Use